Advertisement Suven starts phase 1 clinical trial of Alzheimer's drug in US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Suven starts phase 1 clinical trial of Alzheimer’s drug in US

Biopharmaceutical firm Suven Life Sciences has started phase-1 clinical trial for SUVN-D4010, used for cognition in Alzheimer's disease.

The drug is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist to treat cognitive dysfunction related with Alzheimer’s disease and other dementias.

Suven Life Sciences CEO Venkat Jasti said: "We are very pleased that the third compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer’s and Schizophrenia, a high unmet medical need which has huge market potential globally."

Apart from the SUVN-D4010, Suven’s other two clinical stage compounds include a Phase 2 initiated candidate SUVN-502 and Phase 1 completed candidate SUVN-G3031.

The company also has ten internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as attention deficit hyperactivity disorder, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.

Suven discovers, develops and commercializes novel pharmaceutical products, which are first in class or best in class CNS therapies by using GPCR targets.